Brand name: Rezulin
Public Citizen has been assessing the quality and efficacy of drugs and devices since its founding in 1971. We use the law, petitions, and letters to monitor the FDA and coax the agency into action. Our actions have contributed to many drugs being pulled off the market. Public Citizen has also been instrumental in getting “black box” and other warnings on drugs. Our advocacy work on this drug is available below.
If you are interesting in reading our evaluations of the safety and efficacy of medications as well as information on drug side effects and interactions, please visit WorstPills.org.
More information on troglitazone (Rezulin)
- Letter in the Lancet on the Availability of Information on Thiazolidinediones, July 15, 2000
- Letter Requesting a Criminal Investigation of Warner Lambert/Parke Davis, March 14, 2000
- Petition Requesting Updated Labeling for Diabetes drugs Troglitazone (Rezulin), Rosiglitazone (Avandia) and Pioglitazone (Actos), March 7, 2000
- Letter in JAMA Responding to Article on the Safety of Withdrawn Drugs, December 2, 1999
- Testimony Advising the FDA to Withdraw Troglitazone (Rezulin), March 26, 1999
- Letter on Ad for Troglitazone (Rezulin), January 6, 1999
- Petition to Ban Troglitazone (Rezulin), July 27, 1998